Randomized, “head-to-head” studies comparing different SGLT2 inhibitors are definitely needed

Kazuomi Kario; Noriko Harada; Satoshi Hoshide

doi:10.1111/jch.14077

Randomized, “head-to-head” studies comparing different SGLT2 inhibitors are definitely needed

Kazuomi Kario, Noriko Harada, Satoshi Hoshide

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	2391-2392
Number of pages	2
Journal	Journal of Clinical Hypertension
Volume	22
Issue number	12
DOIs	https://doi.org/10.1111/jch.14077
State	Published - Dec 2020
Externally published	Yes

Access to Document

10.1111/jch.14077

Cite this

@article{8d14e2ebdf3b4dfe96ba88879caab81d,

title = "Randomized, “head-to-head” studies comparing different SGLT2 inhibitors are definitely needed",

author = "Kazuomi Kario and Noriko Harada and Satoshi Hoshide",

note = "Funding Information: Prof. K Kario has received research grants from Astellas Pharma Inc, Eisai Co., Otsuka Pharmaceutical Co., Sanofi KK, Shionogi & Co., Sanwa Kagaku Kenkyusho Co., Daiichi Sankyo Co., Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Boehringer Ingelheim Japan Inc, Pfizer Japan Inc, Bristol‐Myers Squibb KK, and Mochida Pharmaceutical Co. and lecture fees from Idorsia Pharmaceuticals Japan, Daiichi Sankyo Co., and Takeda Pharmaceutical Co. All other authors have no conflicts of interest to disclose.",

year = "2020",

month = dec,

doi = "10.1111/jch.14077",

language = "English",

volume = "22",

pages = "2391--2392",

journal = "Journal of Clinical Hypertension",

issn = "1524-6175",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "12",

}

TY - JOUR

T1 - Randomized, “head-to-head” studies comparing different SGLT2 inhibitors are definitely needed

AU - Kario, Kazuomi

AU - Harada, Noriko

AU - Hoshide, Satoshi

N1 - Funding Information: Prof. K Kario has received research grants from Astellas Pharma Inc, Eisai Co., Otsuka Pharmaceutical Co., Sanofi KK, Shionogi & Co., Sanwa Kagaku Kenkyusho Co., Daiichi Sankyo Co., Sumitomo Dainippon Pharma Co., Takeda Pharmaceutical Co., Mitsubishi Tanabe Pharma Co., Boehringer Ingelheim Japan Inc, Pfizer Japan Inc, Bristol‐Myers Squibb KK, and Mochida Pharmaceutical Co. and lecture fees from Idorsia Pharmaceuticals Japan, Daiichi Sankyo Co., and Takeda Pharmaceutical Co. All other authors have no conflicts of interest to disclose.

PY - 2020/12

Y1 - 2020/12

UR - http://www.scopus.com/inward/record.url?scp=85093852943&partnerID=8YFLogxK

U2 - 10.1111/jch.14077

DO - 10.1111/jch.14077

M3 - Letter

C2 - 33086425

AN - SCOPUS:85093852943

SN - 1524-6175

VL - 22

SP - 2391

EP - 2392

JO - Journal of Clinical Hypertension

JF - Journal of Clinical Hypertension

IS - 12

ER -